Figure 2
From: Cardioprotective effects of miR-34a silencing in a rat model of doxorubicin toxicity
Ant34a ameliorated cardiac function reducing miR-34a levels in hearts of DOXO treated rats. (a) Pulsed-wave Doppler at 3 weeks showing diastolic function: peak velocity of E Dec t and IVRT. (b) Echocardiographic systolic indices EF and FS at 3 weeks. (c ) Pulsed-wave Doppler at 6 weeks showing diastolic function: peak velocity of E Dec t and IVRT. (d) Echocardiographic systolic indices EF and FS at 6 weeks. (e) The presence in the myocardium of Ant34a, labelled with the FAM fluorophore (green), is shown by histological analysis. Cardiomyocytes are labelled with α-SA (red), nuclei are stained with DAPI (blue). Scale bar 25 μm. (f) qPCR analysis indicated miR-34a expression in cardiac tissues of DOXO-treated rats sacrificed at 6 weeks. MiRNA expression is shown as fold change with respect to CTL group. Results are presented as mean ± SD, n = 5–10/group. *p < 0.05 vs CTL; °p < 0.05 vs DOXO; #p < 0.05 vs D + AntCTL. D: DOXO.
